MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, AVBP had -$28,753K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$28,753K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Sales and maturities of short-te...
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Purchase of short-term and long-...
    • Prepaid expenses and other curre...
    • Amortization/accretion of bond d...
    • Others

Cash Flow
2025-12-31
Net loss
-166,308
Stock-based compensation expense
12,520
Amortization/accretion of bond discounts/premiums
-3,026
Prepaid expenses and other current assets
12,561
Accounts payable
2,141
Accrued expenses
6,667
Operating lease liabilities
-21
Net cash used in operating activities
-160,588
Purchase of short-term and long-term investments
272,934
Sales and maturities of short-term and long-term investments
201,706
Net cash used in investing activities
-71,228
Proceeds from issuance of common stock, net of issuance costs
202,631
Proceeds from the exercise of stock options
502
Payment of deferred financing costs
70
Net cash provided by financing activities
203,063
Net decrease in cash and cash equivalents
-28,753
Cash and cash equivalents at beginning of the year
74,293
Cash and cash equivalents at end of the year
45,540
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock, net of...$202,631K Proceeds from theexercise of stock options$502K Net cash provided byfinancing activities$203,063K Canceled cashflow$70K Net decrease in cashand cash...-$28,753K Canceled cashflow$203,063K Stock-based compensationexpense$12,520K Accrued expenses$6,667K Accounts payable$2,141K Sales and maturitiesof short-term and...$201,706K Payment of deferredfinancing costs$70K Net cash used inoperating activities-$160,588K Canceled cashflow$21,328K Net cash used ininvesting activities-$71,228K Canceled cashflow$201,706K Net loss-$166,308K Prepaid expenses andother current assets$12,561K Amortization/accretion of bonddiscounts/premiums-$3,026K Operating leaseliabilities-$21K Purchase of short-termand long-term...$272,934K

ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma, Inc. (AVBP)